3SBIO Aktie

 

Citi published a research report stating that 3SBIO (01530.HK)'s interim revenue grew 4% YoY to RMB4.53 billion. Affected by changes in VAT rates and the industry's anti-corruption campaign, product sales revenue fell 19% YoY, although the company recorded milestone revenue of RMB852 million from SSGJ-707 during the period.Citi ......

3SBIO (01530.HK) announced its interim results for the six months ended June 2026. Revenue amounted to RMB4.526 billion, up 3.9% YoY. Gross profit was RMB3.795 billion, up 2.1%. Net profit amounted to RMB1.147 billion, down 15.6%, with EPS of RMB0.45. No dividend was declared. (d)~AASTOCKS Financial NewsWebsite: www.aastocks.com......

CMBI issued a research report noting that the MSCI China Healthcare Index has cumulatively declined by 11.4% since the beginning of 2026, outperforming the MSCI China Index by 0.2 ppts. The broker believes the recent pullback in the pharmaceutical sector was mainly affected by liquidity factors, policy factors and geopolitics. H......

Morgan Stanley released a research report incorporating 3SBIO (01530.HK)'s 2025 results, and lowering its 2026-2028 revenue forecasts by 5%/ 7% / 6% each, due to reduced sales forecasts for 3SBIO's core commercialized product, TPIAO, and milestone payments, mainly affected by the depreciation of USD/ RMB. The broker also......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

3SBIO (01530.HK) announced the physical distribution of all shares of Mandy International, opening today with a 3.36% increase and peaking at HKD25. By midday, the stock closed at HKD24.96, up 10.25%, with a trading volume of 38.3572 million shares and involving a capital of HKD922 million.3SBIO announced a special dividend dist......

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both......

3SBio (01530.HK) announced that it will distribute a special dividend through an in-kind distribution, allocating all shares of Mandy International held by the company to eligible shareholders in proportion to their shareholdings before the proposed spin-off is completed.In November last year, the company announced the proposed ......

3SBio (01530.HK) announced its 2025 annual results, reporting revenue of RMB17.696 billion, up 94.3% year-on-year, primarily due to licensing revenue from a breakthrough PD-1/VEGF bispecific antibody 707 licensing deal with Pfizer. The company recorded a net profit of RMB8.482 billion, a growth of 305.8%, with an EPS of RMB3.51.......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer (PFE.US) earlier disclosed its blockbuster development plan for 707/PF'4404(PD-1/VEGF) in collaboration with 3SBIO (01530.HK), with speed and breadth of advancement exceeding CMBI's expectations, according to CMBI's research report.The broker believed that PD-1/VEGF bispecific antibody will become cornerstone ......

Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on “Bloomberg: The China Show” from San Francisco, where the JPMorgan Healthcare Conference is taking place. (Source: Bloomberg)...

Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 SINO BIOPHARM(01177.HK) | Buy | 9.4 WUXI XDC(02268.HK) | Buy | 74 ~AAStocks Financial NewsWeb Site: www.aastocks.com...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 WUXI XDC(02268.HK) | Buy | 74 SINO BIOPHARM(01177.HK) | Buy | 9.4 ~AAStocks Financial NewsWeb Site: www.aastocks.com...

read more...

After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways:    By Molly Wen Buoyed by a stock rally, Chinese drug developer 3SBio Inc. (1530.HK) is bulking up on funds to meet the challenge of delivering..... The post 3SBio gears up for drugs battle with $400 million equity move appeared first on Bamboo Works....

Chinese drug maker 3SBio plans to raise HK$3.12 billion (US$401 million) by selling a 4.14 per cent stake in the company to fund clinical research in China and the US and expand the global reach of its drug portfolio. The Shenyang-based biopharmaceutical firm has agreed to sell 105.1 million new shares at HK$29.62 each. The placing price represents a 6.5 per cent discount compared with Monday's closing price of HK$31.68, according to its filing with the Hong Kong stock exchange on Tuesday. The......

3SBIO (01530.HK) plans a share placement at a 6.5% discount, with net proceeds reaching HKD3.087 billion. This news dented the company's stock price by 3.09% at open today (2nd), bottoming at HKD29.98. It last traded at HKD30.04, down 5.18%, with a trading volume of 4.6345 million shares, amounting to HKD140 million.3SBIO an......

3SBIO (01530.HK) announced plans to place over 105 million shares, representing approximately 4.14% of the enlarged issued share capital, at a placement price of HKD29.62 per share, which is a 6.5% discount to the previous trading day's closing price of HKD31.68. The net proceeds are expected to reach HKD3.087 billion.Approx......